Table 3 Incidence of adverse events

From: CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial

	CEOP/IVE/GDP (N = 51)			CEOP (N = 51)
	Grade 1–2	Grade 3	Grade 4	Grade 1–2	Grade 3	Grade 4
Hematological event
Neutropenia	11 (22%)	9 (18%)	22 (43%)	12 (24%)	9 (18%)	23 (45%)
Thrombocytopenia	12 (24%)	2 (4%)	2 (4%)	10 (20%)	1 (2%)	3 (6%)
Anemia	34 (67%)	4 (8%)	1 (2%)	31 (61%)	5 (10%)	0
Febrile neutropenia	/	10 (20%)	0	/	12 (24%)	2 (4%)
Non-hematological events
Infection*	9 (18%)	4 (8%)	2 (4%)	10 (20%)	6 (12%)	1 (2%)
Nausea or vomiting	15 (29%)	2 (4%)	0	19 (37%)	1 (2%)	0
ALT or AST increase	9 (18%)	2 (4%)	0	8 (16%)	1 (2%)	0
Mucositis	13 (25%)	0	0	15 (29%)	1 (2%)	0
Fatigue	37 (73%)	1 (2%)	0	34 (67%)	1 (2%)	0
Headache	13 (25%)	1 (2%)	0	5 (10%)	1 (2%)	0

Data are n (%). All patients who received at least one dose of study drug were included in the safety analysis. *One patient in CEOP group died from severe infection after 1 cycle of treatment. ALT alanine aminotransferase, AST aspartate transaminase

Back to article page